Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
Nature. 2021 Aug;596(7870):126-132. doi: 10.1038/s41586-021-03752-4. Epub 2021 Jul 21.
PD-1 blockade unleashes CD8 T cells, including those specific for mutation-associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit these T cell responses. Single-cell transcriptomics have revealed global T cell dysfunction programs in tumour-infiltrating lymphocytes (TIL). However, the majority of TIL do not recognize tumour antigens, and little is known about transcriptional programs of MANA-specific TIL. Here, we identify MANA-specific T cell clones using the MANA functional expansion of specific T cells assay in neoadjuvant anti-PD-1-treated non-small cell lung cancers (NSCLC). We use their T cell receptors as a 'barcode' to track and analyse their transcriptional programs in the tumour microenvironment using coupled single-cell RNA sequencing and T cell receptor sequencing. We find both MANA- and virus-specific clones in TIL, regardless of response, and MANA-, influenza- and Epstein-Barr virus-specific TIL each have unique transcriptional programs. Despite exposure to cognate antigen, MANA-specific TIL express an incompletely activated cytolytic program. MANA-specific CD8 T cells have hallmark transcriptional programs of tissue-resident memory (TRM) cells, but low levels of interleukin-7 receptor (IL-7R) and are functionally less responsive to interleukin-7 (IL-7) compared with influenza-specific TRM cells. Compared with those from responding tumours, MANA-specific clones from non-responding tumours express T cell receptors with markedly lower ligand-dependent signalling, are largely confined to HOBIT TRM subsets, and coordinately upregulate checkpoints, killer inhibitory receptors and inhibitors of T cell activation. These findings provide important insights for overcoming resistance to PD-1 blockade.
PD-1 阻断释放 CD8 T 细胞,包括那些针对突变相关新抗原 (MANA) 的 T 细胞,但肿瘤微环境中的因素可以抑制这些 T 细胞反应。单细胞转录组学已经揭示了肿瘤浸润淋巴细胞 (TIL) 中的全局 T 细胞功能障碍程序。然而,大多数 TIL 不能识别肿瘤抗原,并且对于 MANA 特异性 TIL 的转录程序知之甚少。在这里,我们使用新辅助抗 PD-1 治疗的非小细胞肺癌 (NSCLC) 中特定 T 细胞的 MANA 功能扩增来鉴定 MANA 特异性 T 细胞克隆。我们使用它们的 T 细胞受体作为“条形码”,使用耦合的单细胞 RNA 测序和 T 细胞受体测序来跟踪和分析它们在肿瘤微环境中的转录程序。我们在 TIL 中发现了 MANA- 和病毒特异性克隆,无论反应如何,并且 MANA-、流感-和 Epstein-Barr 病毒特异性 TIL 都具有独特的转录程序。尽管暴露于同源抗原,MANA 特异性 TIL 表达不完全激活的细胞溶解程序。MANA 特异性 CD8 T 细胞具有组织驻留记忆 (TRM) 细胞的标志性转录程序,但低水平的白细胞介素 7 受体 (IL-7R),并且与流感特异性 TRM 细胞相比,对白细胞介素 7 (IL-7) 的反应性较低。与来自反应性肿瘤的克隆相比,来自非反应性肿瘤的 MANA 特异性克隆的 T 细胞受体具有明显降低的配体依赖性信号传导,主要局限于 HOBIT TRM 亚群,并且协调上调检查点、杀伤抑制受体和 T 细胞激活抑制剂。这些发现为克服 PD-1 阻断耐药性提供了重要的见解。